Christopher Lieu, MD, University of Colorado, shares insights to how ctDNA can detect MRD and determine genomic characterization of tumors in CRC.

Carla Casulo, MD, Associate Professor, Wilmot Cancer Institute, University of Rochester, New York, overviews the various treatments that have been approved for the management of patients with newly diagnosed and relapsed follicular lymphoma (FL).

Connie Batlevi, MD, PhD shares updated safety and efficacy data from the SYMPHONY-1 trial of tazemetostat, a first-class, oral, selective EZH2 inhibitor, for patients with FL.

Dr Loprinzi Reviews Hot Flash Treatment Strategies in BC, Part II by HMP Global

Dr Loprinzi Reviews Hot Flash Treatment Strategies for Patients With Breast Cancer by HMP Global

Dr Jacob Reviews SunRISe-1 Trial Progress in HR-NMIBC by HMP Global

Kim Chi, MD, Vancouver Prostate Centre, Discusses Phase 3 MAGNITUDE study of niraparib as well as the SPARTAN and TITAN studies, presented at 2022 ASCO GU Meeting.

Dr Melani discusses results and safety outcomes of the ViPOR trial with venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide to treat R/R and untreated MCL, presented at the 2021 Annual ASH Meeting.

Thomas Slavin, MD, reviews ways to improve polygenic risk scores (PRS) in breast cancer by reducing ancestral bias.

John Mascarenhas, MD, provides insight on the treatment of myelofibrosis patients with the TGF-β 1/3 Inhibitor AVID200 (MPN-RC 118), presented at the 2021 Annual ASH Meeting.